Spyre Therapeutics develops innovative long-acting antibodies and antibody combinations aimed at transforming treatment for inflammatory bowel disease and rheumatic diseases. Our unique pipeline focuses on extended half-life therapies that target critical pathways, offering new possibilities for patients in need.
